{"filing":{"accession_number":"0001193125-26-318078","cik":"0001815442","ticker":"KYMR","company_name":"Kymera Therapeutics, Inc.","form":"8-K","filing_date":"2026-07-27","report_date":"2026-07-27","primary_document":"d167778d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1815442/000119312526318078/d167778d8k.htm"},"events":[{"id":20693,"run_id":18626,"accession_number":"0001193125-26-318078","anchor_item_number":"5.02","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.92,"summary":"Kymera Therapeutics appointed Terence Rooney, M.D., as Chief Medical Officer effective July 27, 2026, succeeding Jared Gollob who retired after eight years. Dr. Rooney will lead the company's clinical development strategy across its pipeline.","company_name":"Kymera Therapeutics, Inc.","ticker":"KYMR","filing_date":"2026-07-27","form":"8-K","submitted_at":null,"items":[{"id":20135,"accession_number":"0001193125-26-318078","item_number":"5.02","item_title":null,"event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The filing discloses the appointment of Terence Rooney, M.D., as Chief Medical Officer effective July 27, 2026, succeeding Jared Gollob. While the section also mentions Dr. Gollob's retirement, the principal disclosed action centers on the appointment of a new CMO—a named executive officer role critical to clinical development strategy at a clinical-stage biopharmaceutical company. The press release emphasizes Dr. Rooney's qualifications and his leadership of the company's clinical development strategy going forward.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-27T20:15:30.408050+00:00","company_name":"","ticker":null,"filing_date":""},{"id":20136,"accession_number":"0001193125-26-318078","item_number":"7.01","item_title":null,"event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The disclosure centers on the appointment of Dr. Terence Rooney as Chief Medical Officer of Kymera Therapeutics, a clinical-stage biopharmaceutical company. While the press release also mentions the retirement of Dr. Jared Gollob after eight years, the principal action disclosed is Rooney's appointment to lead clinical development strategy across the company's pipeline. The appointment of a CMO at a clinical-stage biotech company advancing multiple programs is material to investors assessing the company's clinical execution capability.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-27T20:15:30.408050+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":20135,"accession_number":"0001193125-26-318078","item_number":"5.02","item_title":null,"event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The filing discloses the appointment of Terence Rooney, M.D., as Chief Medical Officer effective July 27, 2026, succeeding Jared Gollob. While the section also mentions Dr. Gollob's retirement, the principal disclosed action centers on the appointment of a new CMO—a named executive officer role critical to clinical development strategy at a clinical-stage biopharmaceutical company. The press release emphasizes Dr. Rooney's qualifications and his leadership of the company's clinical development strategy going forward.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-27T20:15:30.408050+00:00","company_name":"Kymera Therapeutics, Inc.","ticker":"KYMR","filing_date":"2026-07-27"},{"id":20136,"accession_number":"0001193125-26-318078","item_number":"7.01","item_title":null,"event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The disclosure centers on the appointment of Dr. Terence Rooney as Chief Medical Officer of Kymera Therapeutics, a clinical-stage biopharmaceutical company. While the press release also mentions the retirement of Dr. Jared Gollob after eight years, the principal action disclosed is Rooney's appointment to lead clinical development strategy across the company's pipeline. The appointment of a CMO at a clinical-stage biotech company advancing multiple programs is material to investors assessing the company's clinical execution capability.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-27T20:15:30.408050+00:00","company_name":"Kymera Therapeutics, Inc.","ticker":"KYMR","filing_date":"2026-07-27"}]}